Attenzione: i dati modificati non sono ancora stati salvati. Per confermare inserimenti o cancellazioni di voci è necessario confermare con il tasto SALVA/INSERISCI in fondo alla pagina
Catalogo dei prodotti della ricerca
BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001). The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28 ml per minute per 1.73 m2 of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin. CONCLUSIONS Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes.
Cardiovascular and renal outcomes with empagliflozin in heart failure / M., Packer; S. D., Anker; J., Butler; G., Filippatos; S. J., Pocock; P., Carson; J., Januzzi; S., Verma; H., Tsutsui; M., Brueckmann; W., Jamal; K., Kimura; J., Schnee; C., Zeller; D., Cotton; E., Bocchi; M., Bohm; D. -J., Choi; V., Chopra; E., Chuquiure; N., Giannetti; S., Janssens; J., Zhang; J. R., Gonzalez Juanatey; S., Kaul; H. -P., Brunner-La Rocca; B., Merkely; S. J., Nicholls; S., Perrone; I., Pina; P., Ponikowski; N., Sattar; M., Senni; M. -F., Seronde; J., Spinar; I., Squire; S., Taddei; C., Wanner; F., Zannad; D Aizenberg, EMPEROR-Reduced Trial Investigators:; Cartasegna, L; Colombo, H; Fernandez Moutin, M; Glenny, J; Alvarez Lorio, C; Anauch, D; Campos, R; Facta, A; Fernandez, A; Ahuad Guerrero, R; Lobo Márquez, L; A Leon de la Fuente, R; Mansilla, M; Hominal, M; Hasbani, E; Najenson, M; Luquez, H; Guzman, L; Sessa, H; Amuchástegui, M; Salomone, O; Perna, E; Piskorz, D; Sicer, M; Perez de Arenaza, D; Zaidman, C; Nani, S; Poy, C; Resk, J; Villarreal, R; Majul, C; Colombo Berra, F; Smith Casabella, T; Carnero, G; Caccavo, A; Berli, M; Budassi, N; Bono, J; Alvarisqueta, A; Amerena, J; Kostner, K; Hamilton, A; Begg, A; Colquhoun, D; Sverdlov, A; Vaddadi, G; Wong, J; Coller, J; Prior, D; Friart, A; Leone, A; Janssens, S; Vervoort, G; Timmermans, P; Sarens, T; Vandekerckhove, H; Van De Borne, P; Chenot, F; De Sutter, J; Z Maria Middelares, A; De Vuyst, E; Debonnaire, P; Dupont, M; Pereira Dutra, O; H Canani, L; da Consolação Vieira Moreira, M; de Souza, W; M Backes, L; Maia, L; R Manenti, E; Villaça Guimarães Filho, F; Franco Hirakawa, T; A Saliba, L; C Neuenschwander, F; A de Freitas Zerbini, C; Gonçalves, G; Gonçalves Mello, Y; Ascenção de Souza, J; Beck da Silva Neto, L; A Bocchi, E; Da Silveira, J; Hernandes, M; C Finimundi, H; R Sampaio, C; Vasconcellos, E; J Neves Mancuso, F; M Noya Rabelo, M; Rodrigues Bacci, M; Santos, F; Vidotti, M; V Simões, M; Preto, R; L Gomes, F; Vieira Nascimento, C; Precoma, D; A Ribas Fortes, J; E Leães, P; F Kerr Saraiva, J; A Alves da Costa, F; Reis, G; Zieroth, S; Dion, D; Savard, D; Bourgeois, R; Constance, C; Anderson, K; Verma, S; Leblanc, M; Yung, D; Swiggum, E; Pliamm, L; Tyrrell, B; Huynh, T; Spiegelman, J; Giannetti, N; Lavoie, J; Hartleib, M; Bhargava, R; Straatman, L; Virani, S; Costa-Vitali, A; Hill, L; Heffernan, M; Khaykin, Y; Ricci, J; Zhai, A; Lubelsky, B; Toma, M; Yao, L; Noronha, L; Babapulle, M; Pandey, A; Curnew, G; Berlingieri, J; Kouz, S; Lonn, E; Chehayeb, R; Zheng, Y; Sun, Y; Fan, Z; Han, X; Jiang, X; Tang, Q; Zheng, Z; Zhang, J; Zhang, Y; Shen, A; Yu, J; Ye, J; Yao, Y; Yan, J; Xu, X; Ma, J; Li, Y; Li, S; Lu, S; Kong, X; Yang, G; Yao, Z; Zhang, Y; Pan, Y; Guo, X; Sun, Z; Dong, Y; Peng, D; Yuan, Z; Lin, J; Jerabek, O; Burianova, H; Fiala, T; Hubac, J; Ludka, O; Vodnansky, P; Zeman, K; Foldyna, D; Krupicka, J; Busak, L; Radvan, M; Vomacka, Z; Prosecky, R; Cifkova, R; Durdil, V; Vesely, J; Vaclavik, J; Cervinka, P; Linhart, A; Brabec, T; Miklik, R; Bonnefoy Cudraz, E; Jobbe Duval, A; Tomasevic, D; Habib, G; Isnard, R; Picard, F; Khanoyan, P; Dubois-Rande, J; Galinier, M; Roubille, F; Alexandre, J; Babuty, D; Delarche, N; Seronde, M; Berneau, J; Girerd, N; Bourhaial, H; Olbrich, H; Genth-Zotz, S; Kemala, E; Lemke, B; Böhm, M; Schellong, S; Rieker, W; Faghih, M; Birkenfeld, A; Begemann, A; Ghanem, A; Ujeyl, A; von Haehling, S; Ince, H; Dorsel, T; Bauersachs, J; Prull, M; Darius, H; Wilke, A; Sauter, J; Frey, N; P Schulze, C; König, W; Maier, L; Proskynitopoulos, N; Ebert, H; Sarnighausen, H; Düngen, H; Licka, M; Marx, N; Stellbrink, C; Winkelmann, B; Menck, N; Koenyves, L; Lakatos, F; Matoltsy, A; Noori, E; Andrassy, P; Kancz, S; Simon, G; Sydo, T; Vorobcsuk, A; Merkely, B; Gabor Kiss, R; Szakal, I; Laszlo, N; Barany, T; Nagy, A; Szolnoki, E; Chopra, V; Rastogi, V; Shah, B; Mullasari, A; Shankar, J; Mehta, V; Oomman, A; Nadu, T; Kaul, U; Komarlu, S; Kahali, D; Bhagwat, A; Vijan, V; Kamalakar Ghaisas, N; Mehta, A; Kothari, Y; Taddei, S; Scherillo, M; Zacà, V; Genovese, S; Salvioni, A; Fucili, A; Fedele, F; Cosmi, F; Volpe, M; Senni, M; Mazzone, C; Esposito, G; Doi, M; Yamamoto, H; Sakagami, S; Oishi, S; Yasaka, Y; Tsuboi, H; Fujino, Y; Matsuoka, S; Watanabe, Y; Himi, T; Ide, T; Ichikawa, M; Kijima, Y; Koga, T; Yuda, S; Fukui, K; Kubota, T; Manita, M; Fujinaga, H; Matsumura, T; Fukumoto, Y; Kawai, Y; Hiasa, G; Kazatani, Y; Mori, M; Ogimoto, A; Inoko, M; Oguri, M; Kinoshita, M; Okuhara, K; Watanabe, N; Ono, Y; Otomo, K; Sato, Y; Matsunaga, T; Takaishi, A; Miyagi, N; Uehara, H; Takaishi, H; Yagi, M; Arikawa, M; Hashizume, T; Koizumi, T; Nakayama, K; Taguchi, S; Nanasato, M; Yoshida, Y; Tsujiyama, S; Nakamura, T; Oku, K; Shimizu, M; Suwa, M; Momiyama, Y; Sugiyama, H; Kobayashi, K; Inoue, S; Kadokami, T; Maeno, K; Kawamitsu, K; Maruyama, Y; Nakata, A; Shibata, Y; Wada, A; Urata, H; Kataoka, T; Matsumoto, T; Takahashi, N; Imamaki, M; Watanabe, N; Yoshitama, T; Saito, T; Sekino, H; Furutani, Y; Koda, M; Matsuoka, S; Shinozaki, T; Hirabayashi, K; Tsunoda, R; Yonezawa, K; Hori, H; Llamas Esperon, G; Illescas Díaz, J; Fajardo, P; Almeida Alvarado, J; Bazzoni Ruiz, A; Lopez Alcocer, I; Valle Molina, L; Hernandez Herrera, C; Calvo Vargas, C; G Padilla Padilla, F; Rodriguez Briones, I; Chuquiure Valenzuela, E; Aguilera Real, M; Carrillo Calvillo, J; Alpizar Salaza, M; Cervantes Escárcega, J; Velasco Sanchez, R; Al-Windy, N; van Heerebeek, L; Bellersen, L; Brunner-La Rocca, H; Post, J; M Linssen, G C; van de Wetering, M; Peters, R; van Stralen, R; Groutars, R; Smits, P; Yilmaz, A; M Kok, W E; Van der Meer, P; Dijkmans, P; Troquay, R; P van Alem, A; Van de Wal, R; Handoko, L; D Westendorp, I C; M van Bergen, P F M; M Rensing, B J W; Hoogslag, P; Kietselaer, B; A Kragten, J; R den Hartog, F; Danilowicz-Szymanowicz, L; Raczak, G; Piesiewicz, W; Zmuda, W; Kus, W; Podolec, P; Musial, W; Drelich, G; Kania, G; Miekus, P; Mazur, S; Janik, A; Spyra, J; Peruga, J; Balsam, P; Krakowiak, B; Szachniewicz, J; Ginel, M; Grzybowski, J; Wojewoda, P; Kalinka, A; Zurakowski, A; Koc, R; Debinski, M; Fil, W; Kujawiak, M; Forys, J; Kasprzak, M; Krol, M; Michalski, P; Mirek-Bryniarska, E; Radwan, K; Skonieczny, G; Stania, K; Skoczylas, G; Madej, A; Jurowiecki, J; Firek, B; Wozakowska-Kaplon, B; Cymerman, K; Cho, H; Oh Na, J; Yoo, B; Choi, J; Shin, J; Cho, M; Choi, D; Hwan Han, S; Jeong, J; Kim, J; Min Kang, S; Kim, D; Hyun Kim, M; López-Sendón, J; de la Fuente Galán, L; Delgado Jiménez, J; Manito Lorite, N; Pérez de Juan Romero, M; Cereto Castro, F; González Juanatey, J; Gómez, J; Sanmartín Fernández, M; Garcia-Moll Marimon, X; Pascual Figal, D; Bover Freire, R; Saxena, M; Yousef, Z; Clifford, C; Arden, C; Bakhai, A; Squire, I; Jenkins, G; Travill, C; Price, D; Neutel, J; Adams, K; Balfour, P; Djamson, A; Duncan, P; Hong, M; Woodhouse, S; Macnevin, R; Rama, B; Anderson, K; Broome-Webster, C; Kindsvater, S; Barettella, M; Pinney, S; Cohen, A; Vora, K; Challappa, K; West, S; Baum, S; Cox, J; Jani, S; Karim, A; Akhtar, A; Goldberg, R; Bhatti, Z; Budoff, M; Bush, E; Potler, A; Ellis, B; Dy, J; Fialkow, J; Sangrigoli, R; Ferdinand, K; East, C; Falkowski, S; Donahoe, S; Ebrahimi, R; Kline, G; Harris, B; Khouzam, R; Jaffrani, N; Jarmukli, N; Kazemi, N; Koren, M; Friedman, K; Herzog, W; Cheung, D; Grover-McKay, M; Hauptman, P; Mikhalkova, D; Khouri, S; Mcgrew, F; Mccullough, P; Littlefield, R; Bradley, P; Mclaurin, B; Lupovitch, S; Labin, I; Rao, V; Leithe, M; Lewis, N; Lombardo, D; Mahal, S; Malhotra, V; Mehta, V; Dauber, I; Banerjee, A; Needell, J; Miller, G; Paladino, L; Munuswamy, K; Nanna, M; Mcmillan, E; Mumma, M; Napoli, M; Nelson, W; O'Brien, T; Adlakha, A; Onwuanyi, A; Serota, H; Schmedtje, J; Paraschos, A; Potu, R; Sai-Sudhakar, C; Sauer, A; Shah, P; Skopicki, H; Bui, H; Carr, K; Stevens, G; Tahirkheli, N; Tallaj, J; Yousuf, K; Trichon, B; Welker, J; Vest, A; Wang, X; Abadier, R; Dunlap, S; Weintraub, N; Malik, A; Kotha, P; Zaha, V; Kim, G; Uriel, N; Greene, T; Salacata, A; Arora, R; Gazmuri, R; Kobayashi, J; Iteld, B; Dab, R; Mirza, Z; Marques, V; Nallasivan, M; Saint-Jacques, H; Barringhaus, K; Contreras, J; Gupta, A; Koneru, S; Nguyen, V. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 383:15(2020), pp. 1413-1424. [10.1056/NEJMoa2022190]
Cardiovascular and renal outcomes with empagliflozin in heart failure
BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001). The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28 ml per minute per 1.73 m2 of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin. CONCLUSIONS Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes.
01 Pubblicazione su rivista::01a Articolo in rivista
Cardiovascular and renal outcomes with empagliflozin in heart failure / M., Packer; S. D., Anker; J., Butler; G., Filippatos; S. J., Pocock; P., Carson; J., Januzzi; S., Verma; H., Tsutsui; M., Brueckmann; W., Jamal; K., Kimura; J., Schnee; C., Zeller; D., Cotton; E., Bocchi; M., Bohm; D. -J., Choi; V., Chopra; E., Chuquiure; N., Giannetti; S., Janssens; J., Zhang; J. R., Gonzalez Juanatey; S., Kaul; H. -P., Brunner-La Rocca; B., Merkely; S. J., Nicholls; S., Perrone; I., Pina; P., Ponikowski; N., Sattar; M., Senni; M. -F., Seronde; J., Spinar; I., Squire; S., Taddei; C., Wanner; F., Zannad; D Aizenberg, EMPEROR-Reduced Trial Investigators:; Cartasegna, L; Colombo, H; Fernandez Moutin, M; Glenny, J; Alvarez Lorio, C; Anauch, D; Campos, R; Facta, A; Fernandez, A; Ahuad Guerrero, R; Lobo Márquez, L; A Leon de la Fuente, R; Mansilla, M; Hominal, M; Hasbani, E; Najenson, M; Luquez, H; Guzman, L; Sessa, H; Amuchástegui, M; Salomone, O; Perna, E; Piskorz, D; Sicer, M; Perez de Arenaza, D; Zaidman, C; Nani, S; Poy, C; Resk, J; Villarreal, R; Majul, C; Colombo Berra, F; Smith Casabella, T; Carnero, G; Caccavo, A; Berli, M; Budassi, N; Bono, J; Alvarisqueta, A; Amerena, J; Kostner, K; Hamilton, A; Begg, A; Colquhoun, D; Sverdlov, A; Vaddadi, G; Wong, J; Coller, J; Prior, D; Friart, A; Leone, A; Janssens, S; Vervoort, G; Timmermans, P; Sarens, T; Vandekerckhove, H; Van De Borne, P; Chenot, F; De Sutter, J; Z Maria Middelares, A; De Vuyst, E; Debonnaire, P; Dupont, M; Pereira Dutra, O; H Canani, L; da Consolação Vieira Moreira, M; de Souza, W; M Backes, L; Maia, L; R Manenti, E; Villaça Guimarães Filho, F; Franco Hirakawa, T; A Saliba, L; C Neuenschwander, F; A de Freitas Zerbini, C; Gonçalves, G; Gonçalves Mello, Y; Ascenção de Souza, J; Beck da Silva Neto, L; A Bocchi, E; Da Silveira, J; Hernandes, M; C Finimundi, H; R Sampaio, C; Vasconcellos, E; J Neves Mancuso, F; M Noya Rabelo, M; Rodrigues Bacci, M; Santos, F; Vidotti, M; V Simões, M; Preto, R; L Gomes, F; Vieira Nascimento, C; Precoma, D; A Ribas Fortes, J; E Leães, P; F Kerr Saraiva, J; A Alves da Costa, F; Reis, G; Zieroth, S; Dion, D; Savard, D; Bourgeois, R; Constance, C; Anderson, K; Verma, S; Leblanc, M; Yung, D; Swiggum, E; Pliamm, L; Tyrrell, B; Huynh, T; Spiegelman, J; Giannetti, N; Lavoie, J; Hartleib, M; Bhargava, R; Straatman, L; Virani, S; Costa-Vitali, A; Hill, L; Heffernan, M; Khaykin, Y; Ricci, J; Zhai, A; Lubelsky, B; Toma, M; Yao, L; Noronha, L; Babapulle, M; Pandey, A; Curnew, G; Berlingieri, J; Kouz, S; Lonn, E; Chehayeb, R; Zheng, Y; Sun, Y; Fan, Z; Han, X; Jiang, X; Tang, Q; Zheng, Z; Zhang, J; Zhang, Y; Shen, A; Yu, J; Ye, J; Yao, Y; Yan, J; Xu, X; Ma, J; Li, Y; Li, S; Lu, S; Kong, X; Yang, G; Yao, Z; Zhang, Y; Pan, Y; Guo, X; Sun, Z; Dong, Y; Peng, D; Yuan, Z; Lin, J; Jerabek, O; Burianova, H; Fiala, T; Hubac, J; Ludka, O; Vodnansky, P; Zeman, K; Foldyna, D; Krupicka, J; Busak, L; Radvan, M; Vomacka, Z; Prosecky, R; Cifkova, R; Durdil, V; Vesely, J; Vaclavik, J; Cervinka, P; Linhart, A; Brabec, T; Miklik, R; Bonnefoy Cudraz, E; Jobbe Duval, A; Tomasevic, D; Habib, G; Isnard, R; Picard, F; Khanoyan, P; Dubois-Rande, J; Galinier, M; Roubille, F; Alexandre, J; Babuty, D; Delarche, N; Seronde, M; Berneau, J; Girerd, N; Bourhaial, H; Olbrich, H; Genth-Zotz, S; Kemala, E; Lemke, B; Böhm, M; Schellong, S; Rieker, W; Faghih, M; Birkenfeld, A; Begemann, A; Ghanem, A; Ujeyl, A; von Haehling, S; Ince, H; Dorsel, T; Bauersachs, J; Prull, M; Darius, H; Wilke, A; Sauter, J; Frey, N; P Schulze, C; König, W; Maier, L; Proskynitopoulos, N; Ebert, H; Sarnighausen, H; Düngen, H; Licka, M; Marx, N; Stellbrink, C; Winkelmann, B; Menck, N; Koenyves, L; Lakatos, F; Matoltsy, A; Noori, E; Andrassy, P; Kancz, S; Simon, G; Sydo, T; Vorobcsuk, A; Merkely, B; Gabor Kiss, R; Szakal, I; Laszlo, N; Barany, T; Nagy, A; Szolnoki, E; Chopra, V; Rastogi, V; Shah, B; Mullasari, A; Shankar, J; Mehta, V; Oomman, A; Nadu, T; Kaul, U; Komarlu, S; Kahali, D; Bhagwat, A; Vijan, V; Kamalakar Ghaisas, N; Mehta, A; Kothari, Y; Taddei, S; Scherillo, M; Zacà, V; Genovese, S; Salvioni, A; Fucili, A; Fedele, F; Cosmi, F; Volpe, M; Senni, M; Mazzone, C; Esposito, G; Doi, M; Yamamoto, H; Sakagami, S; Oishi, S; Yasaka, Y; Tsuboi, H; Fujino, Y; Matsuoka, S; Watanabe, Y; Himi, T; Ide, T; Ichikawa, M; Kijima, Y; Koga, T; Yuda, S; Fukui, K; Kubota, T; Manita, M; Fujinaga, H; Matsumura, T; Fukumoto, Y; Kawai, Y; Hiasa, G; Kazatani, Y; Mori, M; Ogimoto, A; Inoko, M; Oguri, M; Kinoshita, M; Okuhara, K; Watanabe, N; Ono, Y; Otomo, K; Sato, Y; Matsunaga, T; Takaishi, A; Miyagi, N; Uehara, H; Takaishi, H; Yagi, M; Arikawa, M; Hashizume, T; Koizumi, T; Nakayama, K; Taguchi, S; Nanasato, M; Yoshida, Y; Tsujiyama, S; Nakamura, T; Oku, K; Shimizu, M; Suwa, M; Momiyama, Y; Sugiyama, H; Kobayashi, K; Inoue, S; Kadokami, T; Maeno, K; Kawamitsu, K; Maruyama, Y; Nakata, A; Shibata, Y; Wada, A; Urata, H; Kataoka, T; Matsumoto, T; Takahashi, N; Imamaki, M; Watanabe, N; Yoshitama, T; Saito, T; Sekino, H; Furutani, Y; Koda, M; Matsuoka, S; Shinozaki, T; Hirabayashi, K; Tsunoda, R; Yonezawa, K; Hori, H; Llamas Esperon, G; Illescas Díaz, J; Fajardo, P; Almeida Alvarado, J; Bazzoni Ruiz, A; Lopez Alcocer, I; Valle Molina, L; Hernandez Herrera, C; Calvo Vargas, C; G Padilla Padilla, F; Rodriguez Briones, I; Chuquiure Valenzuela, E; Aguilera Real, M; Carrillo Calvillo, J; Alpizar Salaza, M; Cervantes Escárcega, J; Velasco Sanchez, R; Al-Windy, N; van Heerebeek, L; Bellersen, L; Brunner-La Rocca, H; Post, J; M Linssen, G C; van de Wetering, M; Peters, R; van Stralen, R; Groutars, R; Smits, P; Yilmaz, A; M Kok, W E; Van der Meer, P; Dijkmans, P; Troquay, R; P van Alem, A; Van de Wal, R; Handoko, L; D Westendorp, I C; M van Bergen, P F M; M Rensing, B J W; Hoogslag, P; Kietselaer, B; A Kragten, J; R den Hartog, F; Danilowicz-Szymanowicz, L; Raczak, G; Piesiewicz, W; Zmuda, W; Kus, W; Podolec, P; Musial, W; Drelich, G; Kania, G; Miekus, P; Mazur, S; Janik, A; Spyra, J; Peruga, J; Balsam, P; Krakowiak, B; Szachniewicz, J; Ginel, M; Grzybowski, J; Wojewoda, P; Kalinka, A; Zurakowski, A; Koc, R; Debinski, M; Fil, W; Kujawiak, M; Forys, J; Kasprzak, M; Krol, M; Michalski, P; Mirek-Bryniarska, E; Radwan, K; Skonieczny, G; Stania, K; Skoczylas, G; Madej, A; Jurowiecki, J; Firek, B; Wozakowska-Kaplon, B; Cymerman, K; Cho, H; Oh Na, J; Yoo, B; Choi, J; Shin, J; Cho, M; Choi, D; Hwan Han, S; Jeong, J; Kim, J; Min Kang, S; Kim, D; Hyun Kim, M; López-Sendón, J; de la Fuente Galán, L; Delgado Jiménez, J; Manito Lorite, N; Pérez de Juan Romero, M; Cereto Castro, F; González Juanatey, J; Gómez, J; Sanmartín Fernández, M; Garcia-Moll Marimon, X; Pascual Figal, D; Bover Freire, R; Saxena, M; Yousef, Z; Clifford, C; Arden, C; Bakhai, A; Squire, I; Jenkins, G; Travill, C; Price, D; Neutel, J; Adams, K; Balfour, P; Djamson, A; Duncan, P; Hong, M; Woodhouse, S; Macnevin, R; Rama, B; Anderson, K; Broome-Webster, C; Kindsvater, S; Barettella, M; Pinney, S; Cohen, A; Vora, K; Challappa, K; West, S; Baum, S; Cox, J; Jani, S; Karim, A; Akhtar, A; Goldberg, R; Bhatti, Z; Budoff, M; Bush, E; Potler, A; Ellis, B; Dy, J; Fialkow, J; Sangrigoli, R; Ferdinand, K; East, C; Falkowski, S; Donahoe, S; Ebrahimi, R; Kline, G; Harris, B; Khouzam, R; Jaffrani, N; Jarmukli, N; Kazemi, N; Koren, M; Friedman, K; Herzog, W; Cheung, D; Grover-McKay, M; Hauptman, P; Mikhalkova, D; Khouri, S; Mcgrew, F; Mccullough, P; Littlefield, R; Bradley, P; Mclaurin, B; Lupovitch, S; Labin, I; Rao, V; Leithe, M; Lewis, N; Lombardo, D; Mahal, S; Malhotra, V; Mehta, V; Dauber, I; Banerjee, A; Needell, J; Miller, G; Paladino, L; Munuswamy, K; Nanna, M; Mcmillan, E; Mumma, M; Napoli, M; Nelson, W; O'Brien, T; Adlakha, A; Onwuanyi, A; Serota, H; Schmedtje, J; Paraschos, A; Potu, R; Sai-Sudhakar, C; Sauer, A; Shah, P; Skopicki, H; Bui, H; Carr, K; Stevens, G; Tahirkheli, N; Tallaj, J; Yousuf, K; Trichon, B; Welker, J; Vest, A; Wang, X; Abadier, R; Dunlap, S; Weintraub, N; Malik, A; Kotha, P; Zaha, V; Kim, G; Uriel, N; Greene, T; Salacata, A; Arora, R; Gazmuri, R; Kobayashi, J; Iteld, B; Dab, R; Mirza, Z; Marques, V; Nallasivan, M; Saint-Jacques, H; Barringhaus, K; Contreras, J; Gupta, A; Koneru, S; Nguyen, V. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 383:15(2020), pp. 1413-1424. [10.1056/NEJMoa2022190]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1526264
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo
Citazioni
487
3103
2761
social impact
Conferma cancellazione
Sei sicuro che questo prodotto debba essere cancellato?
simulazione ASN
Il report seguente simula gli indicatori relativi alla propria produzione scientifica in relazione alle soglie ASN 2023-2025 del proprio SC/SSD. Si ricorda che il superamento dei valori soglia (almeno 2 su 3) è requisito necessario ma non sufficiente al conseguimento dell'abilitazione. La simulazione si basa sui dati IRIS e sugli indicatori bibliometrici alla data indicata e non tiene conto di eventuali periodi di congedo obbligatorio, che in sede di domanda ASN danno diritto a incrementi percentuali dei valori. La simulazione può differire dall'esito di un’eventuale domanda ASN sia per errori di catalogazione e/o dati mancanti in IRIS, sia per la variabilità dei dati bibliometrici nel tempo. Si consideri che Anvur calcola i valori degli indicatori all'ultima data utile per la presentazione delle domande.
La presente simulazione è stata realizzata sulla base delle specifiche raccolte sul tavolo ER del Focus Group IRIS coordinato dall’Università di Modena e Reggio Emilia e delle regole riportate nel DM 589/2018 e allegata Tabella A. Cineca, l’Università di Modena e Reggio Emilia e il Focus Group IRIS non si assumono alcuna responsabilità in merito all’uso che il diretto interessato o terzi faranno della simulazione. Si specifica inoltre che la simulazione contiene calcoli effettuati con dati e algoritmi di pubblico dominio e deve quindi essere considerata come un mero ausilio al calcolo svolgibile manualmente o con strumenti equivalenti.